Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker – a retrospective multicenter study

Abstract

Introduction

Biologic switching is common in psoriasis patients with non-response to or adverse events under therapy with a biologic. However, evidence on efficacy of switching between newly approved biologics of similar mode of action is scarce. The objective was to assess the efficacy of treating psoriasis patients with an IL-17-receptor A antagonist after failure of any IL-17A antagonist and to identify predictors of treatment response.

Methods

A retrospective multicenter chart review on psoriasis patients who received brodalumab after failure of ixekizumab or secukinumab therapy was conducted in five German University Medical centers.

Results

Overall, 23 patients were identified. PASI75 response to brodalumab was reached by 47.8% (11/23) of all patients at week 12 and at week 24. 3 patients experienced mild adverse events which did not lead to drug discontinuation.

Conclusions

Brodalumab appears to be an efficacious and safe treatment option in psoriasis patients with prior exposure to IL-17A antagonists.

Keywords:

• Brodalumab
• ixekizumab
• secukinumab
• IL-17 switching

Disclosure statement

C. Kromer has been an advisor and/or received speakers’ honoraria from Janssen-Cilag GmbH and Novartis Pharma GmbH. D. Wilsmann-Theis has been advisor and/or received speakers’ honoraria or travel expense reimbursements and/or received grants and/or participated in clinical trials of the companies: AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim Pharma, Celgene, Forward Pharma, GlaxoSmithKline, JanssenCilag, Leo, Lilly, Medac, Merck Sharp and Dohme, Novartis, Pfizer, UCB Pharma and VBL. S. Gerdes has been an advisor and/or received speakers’ honoraria and/or received grants and/or participated in clinical trials of the following companies: Abbott/AbbVie, Affibody AB, Akari Therapeutics Plc, Almirall-Hermal, Amgen, Anaptys Bio, Baxalta, Bayer Health Care, Biogen Idec, Bioskin, Boehringer-Ingelheim, Celgene, Centocor, Dermira, Eli Lilly, Foamix, Forward Pharma, Galderma, Hexal AG, Isotechnika, Janssen-Cilag, Johnson and Johnson, Leo Pharma, Medac, Merck Serono, Mitsubishi Tanabe, MSD, Novartis, Pfizer, Polichem SA, Regeneron Pharmaceutical, Sandoz Biopharmaceuticals, Sanofi-Aventis, Schering-Plough, Sienna Biopharmaceuticals, Takeda, Teva, UCB Pharma, VBL therapeutics, Wyeth Pharma. S. Krebs has been an advisor and/or received speakers’ honoraria and/or received grants and/or participated in clinical trials of the following companies: AbbVie, Affibody AB, Eli Lilly, Janssen, Leo Pharma, Merck, Novartis, Pfizer, UCB. A. Pinter has been an advisor and/or received speakers’ honoraria and/or received grants and/or participated in clinical trials of the following companies: AbbVie, Almirall-Hermal, Amgen, Biogen Idec, Boehringer-Ingelheim, Celgene, GSK, Eli-Lilly, Galderma, Hexal, Janssen, LEO-Pharma, MC2, Medac, Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Roche, Sandoz Biopharmaceuticals, Schering-Plough und UCB Pharma. S. Philipp has received honoraria for advisory board services from AbbVie, Biogen, Eli Lilly, Janssen Cilag, Leo Pharma, Pfizer, MSD, and Novartis; S. Philipp has received honoraria for speaker services from AbbVie, Almirall, Amgen, Biogen, Boehringer-Ingelheim, BMS GmbH, Celgene, Janssen Cilag, Eli Lilly, Hexal, Leo Pharma, MSD, Mundipharma, Novartis, and UCB Pharma; S. Philipp has received honoraria for investigator services from AbbVie, Almirall, Amgen, Biogen, Boehringer-Ingelheim, Celgene, Dermira, Eli Lilly, GSK, Janssen Cilag, Leo Pharma, Pfizer, Maruho, MSD, Novartis, UCB Pharma, and VBL Therapeutics. These honoraria were paid to the institution. R. Mössner has been an advisor and/or received speakers’ honoraria and/or received grants and/or participated in clinical trials of the following companies: Abbott/Abbvie, Allmirall, Biogen IDEC GmbH, Böhringer-Ingelheim, Celgene, Essex Pharma GmbH, Janssen-Cilag GmbH, Leo Pharma GmbH, Lilly, Merck Serono GmbH, MSD SHARP and DOHME GmbH, Novartis Pharma GmbH, Pfizer GmbH and UCB.

Additional information

Funding

The study was supported by a grant of LEO Pharma GmbH. The funding source had no role in the design of this study, execution, analysis or interpretation of data or decision to submit results.